Celltrion USA announced that it has signed an agreement with Cigna Healthcare, the health benefits provider of the Cigna Group and Express Scripts, the pharmacy benefits services business of the Cigna Group's Evernorth and one of the nation's leading health insurers, that will help expand patient access to ZYMFENTRA^® (infliximab-dyyb), the first and only U.S. Food and Drug Administration (FDA)-approved subcutaneous infliximab. The agreement, effective August 1, 2024, lists ZYMFENTRA as the preferred medication on the Cigna's medical formulary serving 16.1 million insured lives.

ZYMFENTRA was approved by the FDA in October 2023 for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) following treatment with an infliximab product administered intravenously.

"Celltrion USA is dedicated to broadening access to innovative and effective treatment options and our partnership with Cigna and Express Scripts will enhance the choices available to physicians and patients," said Francine Galante, Vice President of Market Access at Celltrion USA. "We believe ZYMFENTRA will deliver substantial value to patients as an alternative administration option allowing patients to have greater flexibility in managing their disease."

This follows Celltrion USA's announcement in April 2024 that Express Scripts provided ZYMFENTRA Preferred Brand Access on the Express Scripts National Preferred Formulary.